Evidence map›Paper›PMID 41231363›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Blood-based Alzheimer's disease biomarkers in a behavioral neurology clinic: Real-world implementation, clinical utility, and diagnostic performance.

Igor Prufer Q C Araujo, Tara Ellingson, Nicholas U Schwartz, Connor D Dietz, Gautam Tammewar, Kaancan Deniz, Manizhe Eslami-Amirabadi, Andrew G Breithaupt, Marci Rosenberg, Nhat Minh Bui and 15 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Igor Prufer Q C AraujoEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Tara EllingsonEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Nicholas U SchwartzEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Connor D DietzEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Gautam TammewarEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Kaancan DenizEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Manizhe Eslami-AmirabadiEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Andrew G BreithauptGoizueta Brain Health Institute, Emory University, Atlanta, Georgia, US.
Marci RosenbergEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Nhat Minh BuiEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Yasmeen GonzalezEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Renaud La JoieEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Peter A LjubenkovEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Katherine L PossinEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Julio C RojasEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
David N Soleimani-MeigooniEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Yingbing WangDepartment of Radiology & Biomedical Imaging, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, US.
Adam M StaffaroniEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Melanie L StephensEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Elena TsoyEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Charles C WindonEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Adam L BoxerEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Gil D RabinoviciEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Bruce L MillerEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.
Lawren VandeVredeEdward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, US.

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Serggio Carlo Lanata · 2019 to 2026
$36.9M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Augmenting Nurse Support and EHR Integration for the Pragmatic Trial of the UCSF-BHAU01NS128913 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine Laurel Possin · 2022 to 2026
$8.2M
Multidisciplinary Research Fellowship in Alzheimer’s disease and Related DementiasT32AG023481 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BRUCE L MILLER, HOWARD J ROSEN · 2005 to 2026
$7.4M
Reimagining Precision Medicine Approaches to AD DiagnosisR35AG072362 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI POSSIN, KATHERINE LAUREL, RABINOVICI, GIL DAN · 2021 to 2025
$4.8M
Validation of Novel Plasma Biomarkers for Mixed Etiology DementiaK23AG073514 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VANDEVREDE, LAWREN · 2021 to 2025
$1.0M
Development of Emergent PET Tracers in Frontotemporal Lobar DegenerationK23AG076960 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David Nima Soleimani-Meigooni · 2022 to 2026
$951k
Amyloid PET and Blood-Based Biomarkers of AD among Diverse PopulationsK23AG093166 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Charles Christian Windon · 2025 to 2026
$328k
Alzheimer's AssociationNIA NIH HHS K23 AG073514NIA NIH HHS K23 AG076960NIA NIH HHS K23 AG093166NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG038791NIA NIH HHS R35 AG072362NIA NIH HHS T32 AG023481NIH HHS K23AG073514NIH HHS P01AG038791NIH HHS P30AG062422NIH HHS R01AG019724NINDS NIH HHS U01 NS128913Shenandoah Foundation
6 · The paper itself

Abstract

introductionBlood-based biomarkers (BBMs) for Alzheimer's disease (AD), including plasma phosphorylated tau (p-tau), are increasingly used in clinical practice, but "real-world" implementation patterns, context-of-use (COU), clinical utility, and diagnostic performance are incompletely understood.

methodsA retrospective analysis of the first year of BBM use in a tertiary level cognitive neurology subspecialty clinic was conducted, including review of COU, impact on diagnostic certainty, prescription of AD-related medications, and additional AD-biomarker testing.

resultsP-tau181 was ordered frequently to detect AD in a diverse cohort, across a wide spectrum of COU, including typical, early-onset, and atypical AD presentations; mixed etiology; AD co-pathology; and borderline symptoms. P-tau181 impacted diagnostic confidence, AD-related medication prescription, and follow-on testing. Renal impairment was a common confounder.

conclusionsImplementation of BBMs was feasible and impactful in a memory clinic, especially in a diagnostically complex and diverse patient population, underscoring the need for additional data from real-world settings. HIGHLIGHTS: Blood-based biomarkers (BBMs) were quickly adopted and accelerated precision diagnosis in a large memory clinic. BBM use cases were diverse and included all stages/types of AD and non-AD syndromes. Plasma p-tau has the potential to impact diagnostic certainty and clinical decision making. Diagnostic performance of p-tau is reasonable, though renal function impacts overall accuracy.

Indexed as

Alzheimer DiseaseBiomarkerstau ProteinsAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesBiomarkerstau ProteinsAlzheimer's diseaseblood‐based biomarkersneurodegenerationneurofilament light chainp‐tau181

Identifiers

PMID41231363
PMCPMC12614084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.